Global respiratory inhaler market to reach $48.7 billion by 2026

  • Global competitiveness and percentage market shares of main competitors
  • Market presence in multiple geographies – Strong/Active/Niche/Trivial
  • Peer-to-peer collaborative online interactive updates
  • Access to our digital archives and the MarketGlass research platform
  • Free updates for one year

Editing: 6; Published: February 2022
Executive commitments: 864
Companies: 131 – Players covered include AstraZeneca plc; Beximco Pharmaceuticals Ltd. ; Boehringer Ingelheim GmbH; cipla ltd. ; GlaxoSmithKline plc; Koninklijke Philips NV; Merck & Co., Inc.; Omron Healthcare Europe BV; PARI Medical Holding; Teva Pharmaceutical Industries Ltd. and others.
Cover: All major geographies and key segments
segments: Technology (Manual, Digital); Product (metered dose, dry powder, nebulizers); Application (asthma, COPD, other applications)
Geographies: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; UK; Spain; Russia; and rest of Europe); Asia Pacific (Australia; India; South Korea; and rest of Asia Pacific); Latin America (Argentina; Brazil; Mexico; and rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and rest of Middle East); and Africa.

Free Project Preview – This is an ongoing global program. Preview our research program before making a purchasing decision. We provide free access to qualified executives in strategy, business development, sales and marketing, and product management roles at featured companies. Insights provide insider access to business trends; competing brands; profiles of experts in the field; and market data models and much more. You can also create your own bespoke report using our MarketGlass™ platform which offers thousands of bytes of data with no obligation to purchase our report. Registry overview


Global Respiratory Inhalers Market to Reach $48.7 billion by 2026
The respiratory care market occupies a significant place in the medical field, as respiratory dysfunction is one of the most prevalent health problems in the world. Drivers of growth include increased incidence of certain respiratory diseases, such as COPD and asthma, significant increase in the number of elderly patients (most of whom suffer from at least one type of respiratory disease) , the growing awareness of certain respiratory problems such as obstructive sleep apnea, and the general growth in demand for improved patient care. Breathing inhalers have often proven to save the lives of millions of patients. The main segments of patients using inhalers are those with asthma, COPD and pulmonary arterial hypertension. The growing geriatric population also uses inhalers as they suffer from reduced immunity against chronic and lung diseases. Respiratory inhalers are equipped with complementary spacers or holding chamber devices to reduce deposition in the mouth and throat. Breathing inhalers are increasingly used to treat patients with COPD (chronic obstructive pulmonary disease) and asthma. Combination therapy is more commonly considered because it has shown its reliability in complex patients and better efficacy. The growth of the respiratory products market is further expected to be supported by the proposed shift to home care.

Amid COVID-19 crisis, Global Respiratory Inhalers Market Estimated at US$39.2 billion in 2022, is expected to reach a revised size of US$48.7 billion by 2026, growing at a CAGR of 6% over the analysis period. Hand-held inhalers, one of the segments analyzed in the report, is expected to grow at a CAGR of 5.4% to reach US$45.4 billion at the end of the analysis period. After a thorough analysis of the business implications of the pandemic and the induced economic crisis, the growth of the digital inhalers segment is readjusted to a revised CAGR of 13.1% for the next 7-year period. This segment currently accounts for a 6.9% share of the global respiratory inhaler market.

The US market is estimated at $14.2 billion in 2022, when China is expected to reach $6.6 billion by 2026
The Respiratory Inhalers Market in the United States is estimated at US$14.2 billion in 2022. The country currently accounts for a 36.11% share of the global market. Chinaworld’s second largest economy, is expected to reach an estimated market size of US$6.6 billion in 2026 with a CAGR of 8.2% over the analysis period. Other notable geographic markets include Japan and Canada, each predicting growth of 4.1% and 5.8% respectively over the analysis period. In Europe, Germany is expected to grow at around 4.4% CAGR while the rest of the European market (as defined in the study) will reach 7 billion US dollars at the end of the analysis period. Growth in these regional markets is expected to be driven by the rise of smart inhalers. With new smart inhaler technology, patients can monitor their doses. Some variants of smart inhalers can measure environmental pollution and alert patients accordingly to airborne asthma triggers. Few smart inhalers are also equipped with a Bluetooth transmitter to connect to the smartphone. Thus, the frequency of asthma attacks, triggers and causes of the patient can be monitored by the health professional. But it is not easy to train patients in the correct use of nebulizers and inhalers.

Segment of digital inhalers to reach $4.9 billion by 2026
Interactive digital inhalers with sophisticated sensors and artificial intelligence (AI) technology are being rolled out to help users manage the disease through guided instructions and usage data recording. The combination of conventional digital inhalers and AI-enabled machine learning algorithms ensures that patients receive timed instructions and audio-visual cues to use the inhaler appropriately and to take prescribed medication regularly in order to avoid asthma attacks. The AI-enabled drug delivery mechanism holds immense potential in the treatment of COPD and other lung conditions besides asthma. The global digital inhaler market is estimated at US$3.1 billion in 2022, and should reach US$4.9 billion by 2026, reflecting a compound annual growth rate of 13.1% over the analysis period. United States is the largest regional market for the digital segment, accounting for 42.5% of global sales. China is poised to record the fastest compound annual growth rate of 16.4% over the analysis period, reaching US$480.1 million at the end of the analysis period. After

MarketGlass™ Platform
Our MarketGlass™ platform is a free comprehensive knowledge center that can be custom configured to meet the intelligence needs of today’s busy business executives! This interactive, influencer-focused research platform is at the heart of our core research engagements and draws on the unique perspectives of participating executives from around the world. Features include – enterprise-wide peer-to-peer collaborations; overviews of research programs relevant to your business; 3.4 million profiles of experts in the field; profiles of competitive companies; interactive research modules; custom report generation; follow market trends; competing brands; create and publish blogs and podcasts using our primary and secondary content; follow domain events around the world; and much more. Client companies will have privileged access to the project’s data stacks. Currently used by over 67,000 domain experts worldwide.

Our platform is free for qualified executives and is accessible from our website or via our mobile application which has just been released on iOS or android

About Global Industry Analysts, Inc. and StrategyR™
Global Industry Analysts, Inc., ( is a renowned market research publisher, the only influencer-focused market research company in the world. Proudly serving over 42,000 clients in 36 countries, GIA has been recognized for its accurate forecasting of markets and industries for over 33 years.

Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
E-mail: [email protected]

Join our group of experts

Connect with us on LinkedIn

Follow us on twitter

Journalists and media
[email protected]

SOURCE Global Industry Analysts, Inc.